PL401895A1 - Use of the phospholipid preparation from egg yolk - Google Patents

Use of the phospholipid preparation from egg yolk

Info

Publication number
PL401895A1
PL401895A1 PL401895A PL40189512A PL401895A1 PL 401895 A1 PL401895 A1 PL 401895A1 PL 401895 A PL401895 A PL 401895A PL 40189512 A PL40189512 A PL 40189512A PL 401895 A1 PL401895 A1 PL 401895A1
Authority
PL
Poland
Prior art keywords
egg yolk
phospholipid preparation
phospholipid
preparation
hypertension
Prior art date
Application number
PL401895A
Other languages
Polish (pl)
Other versions
PL217022B1 (en
Inventor
Dorian Nowacki
Helena Martynowicz
Anna Wojakowska
Łukasz Bobak
Andrzej Szuba
Tadeusz Trziszka
Original Assignee
Uniwersytet Przyrodniczy We Wroclawiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Przyrodniczy We Wroclawiu filed Critical Uniwersytet Przyrodniczy We Wroclawiu
Priority to PL401895A priority Critical patent/PL217022B1/en
Publication of PL401895A1 publication Critical patent/PL401895A1/en
Publication of PL217022B1 publication Critical patent/PL217022B1/en

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Wynalazek dotyczy zastosowania preparatu fosfolipidowego z zóltka jaja jako substancji czynnej do wytwarzania leków lub suplementów diety, lub jako skladnik preparatów zlozonych, do stosowania w profilaktyce i leczeniu nadcisnienia tetniczego.The invention relates to the use of a phospholipid preparation from egg yolk as an active substance for the production of drugs or dietary supplements, or as a component of complex preparations for use in the prevention and treatment of hypertension.

PL401895A 2012-12-04 2012-12-04 Use of the phospholipid preparation from egg yolk PL217022B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL401895A PL217022B1 (en) 2012-12-04 2012-12-04 Use of the phospholipid preparation from egg yolk

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL401895A PL217022B1 (en) 2012-12-04 2012-12-04 Use of the phospholipid preparation from egg yolk

Publications (2)

Publication Number Publication Date
PL401895A1 true PL401895A1 (en) 2013-08-19
PL217022B1 PL217022B1 (en) 2014-06-30

Family

ID=48951785

Family Applications (1)

Application Number Title Priority Date Filing Date
PL401895A PL217022B1 (en) 2012-12-04 2012-12-04 Use of the phospholipid preparation from egg yolk

Country Status (1)

Country Link
PL (1) PL217022B1 (en)

Also Published As

Publication number Publication date
PL217022B1 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
TN2015000278A1 (en) Autotaxin inhibitors
GT201400063A (en) BENZILINDAZOLS REPLACED FOR USE AS INHIBITORS OF QUINASA BUB1 IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
EA201390203A1 (en) METHODS OF OBTAINING TUBULIZINS
NI201400032A (en) PYRIDOPYRAZINES ANTI-CANCER VIA LA
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
MX366899B (en) New compounds.
TR201908003T4 (en) Advanced adjuvant formulations containing TLR4 agonists and their method of use.
CY1119957T1 (en) TREATMENT OF PATIENTS WITH THE USE OF ANNOUNCED PHARMACEUTICAL PREPARATION
CL2015000039A1 (en) Estra-1,3,5 (10), 16-tetraeno-3-substituted derivatives, pharmaceutical preparations that comprise them and their use in the preparation of medicaments for treating endometriosis.
TR201910866T4 (en) Combined preparations for cancer treatment.
BR112017017310A2 (en) lipid compositions
BR112015031417A2 (en) pharmaceutical dosage form, pharmaceutical composition, methods for treating a patient in need of cysteamine and for preparing a dosage form
EA201592003A1 (en) MICRO SUPPLEMENTS FOR IMMUNITY
EA201401117A1 (en) COMPOSITIONS CONTAINING PROBIOTICS AND COMPLEX OF BEE POULTRY / CLAY, METHOD OF THEIR PREPARATION AND THEIR APPLICATION IN FOOD AND THERAPY
CY1119064T1 (en) Fibrolytic compositions containing bromelain and natokinase for the prevention and treatment of pulmonary conditions
UY33208A (en) COMPOSITIONS THAT INCLUDE CISTEINE SUGAR PRODUCTS
EA201790699A1 (en) STABILIZED DERIVATIVES OF ADRENOMEDULLINE AND THEIR APPLICATION
EA201491426A1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING PHOSPHATIDILSERIN AND CURKUMIN
BR112014024033A8 (en) VESICULAR FORMULATION, METHOD FOR THE TREATMENT OF ROSACEA AND USE OF ONE OR MORE PHOSPHO, SULPHOLIPIDS AND SURFACTANTS
MX364528B (en) Withanolides useful for the treatment of neurodegenerative diseases.
PH12015502242A1 (en) Lutein composition suitable for infant food formulations
MX2016003207A (en) Compositions comprising choline and derivatives thereof, uses thereof and processes for their preparation.
EA201500927A1 (en) SOLID LIPID NANOPARTICLES (I)
EA201591725A1 (en) SOLID LIPID NANOPARTICLES (II)
EA201400444A1 (en) DERIVATIVES 2-OXOPYPERIDINYL